The 7,000-square-foot facility will support the manufacturing of aseptic and terminally sterilized small volume liquids and powders for parenteral, nasal and pulmonary delivery.

According to Upperton, the new facility has the capability to support formulation development, clinical manufacture and analytical testing, with batch sizes of up to 2,000 vials, pre-filled syringes and pre-filled cartridges for liquid formulations and pre-sterilized powders.

Nikki Whitfield, Upperton’s CEO, said: “The combined experience of our leadership team in sterile facility builds and subsequent operations ensures that we are ideally placed as a CDMO partner of choice for small to mid-sized biotech and pharma looking to get into the clinic quickly with fast access to sterile manufacturing services.”